Repurposing Existing Drugs for the Treatment of COVID-19.
Repurposing Existing Drugs for the Treatment of COVID-19.
复制标题
DOI：
10.1513/annalsats.202005-566fr
复制
发表时间：
2020-10
影响因子：
8.3
通讯作者：
Singanayagam A
中科院分区：
文献类型：
--
作者：
Farne H;Kumar K;Ritchie AI;Finney LJ;Johnston SL;Singanayagam A
由严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）病毒感染引起的冠状病毒病（COVID-19）在全球迅速传播，死亡率很高，这促使人们迫切需要寻找有效的治疗方法。重新利用现有药物是一个特别有吸引力的方法，因为药代动力学和安全性数据已经存在；因此，开发可以直接跨越式地进入疗效的临床试验，产生结果的速度远远快于新药物开发。本文综述了根据广泛的作用机制（抗病毒、免疫增强、抗炎或免疫调节）对被确定为可用于治疗COVID-19的主要候选药物的研究现状。病人的选择，特别是关于疾病阶段的选择，可能是关键。迄今为止，只有地塞米松和瑞德西韦被证明有效，但其他几种有希望的候选药物正在试验中。
The rapid global spread and significant mortality associated with the coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection has spurred an urgent race to find effective treatments. Repurposing existing drugs is a particularly attractive approach as pharmacokinetic and safety data already exist; thus, development can leapfrog straight to clinical trials of efficacy, generating results far more quickly than de novo drug development. This review summarizes the state of play for the principle drugs identified as candidates to be repurposed for treating COVID-19 grouped by broad mechanism of action: antiviral, immune enhancing, and antiinflammatory or immunomodulatory. Patient selection, particularly with regard to disease stage, is likely to be key. To date, only dexamethasone and remdesivir have been shown to be effective, but several other promising candidates are in trials.